Trade with Eva: Analytics in action >>

Thursday, May 28, 2020

-=Arca Biopharma (ABIO) to develop a coronavirus treatment



Arca said it will study an experimental drug called AB201 in patients with Covid-19 and abnormal blood clotting. Abnormal blood clotting is one of the serious complications of Covid-19. Arca has already tested AB201 in more than 700 patients with other conditions.

The drug already has "substantial safety data, which the company believes may enable more rapid development," Arca said in a news release. The biotech company plans to ask the Food and Drug Administration for permission to begin testing as a coronavirus treatment during the third quarter.

Why It Could Work In Coronavirus Treatment
Arca's potential coronavirus treatment works by blocking the tissue factor, or TF, protein, which is tied to the inflammatory response to viral infections. The biotech company has already studied AB201 in more than 700 patients for various conditions in Phase 1 and Phase 2 tests.

Recent research suggests Covid-19 has several factors in common with blood disorders in which the blood's ability to clot has been impaired, Arca said. There's also evidence to indicate AB201 could have natural and anti-inflammatory abilities, the company said.

"Collectively, the company believes these observation provide a strong rationale for investigating AB201 as a treatment for Covid-19, the disease caused by SARS-CoV-2 virus," Arca said.

The need for an effective coronavirus treatment continues to grow alongside the number of cases. As of Thursday morning, there were more than 5.8 million confirmed cases of Covid-19 globally. The U.S. accounts for about 30% of the caseload.

No comments:

Post a Comment